Join me and FORCE to OPPOSE Legislation Allowing Patents on DNA and Biomarkers! In 2013, the U.S. Supreme Court ruled that genes, such as BRCA1 and BRCA2, and other “products of nature” should not be eligible for patents. Unfortunately, lawmakers have introduced a bill that would overturn 150 years of court precedent. The Patent Eligibility Restoration Act (PERA) would allow patents on human genes and biomarkers. In healthcare, this would endanger the significant progress made in precision medicine and reduce patient access to lifesaving genetic tests. If enacted, a single patent holder could control all research and clinical evaluation associated with a gene or biomarker, and create a monopoly in which they are the sole provider of testing.